［1］ Chen P H, Gao S, Wang Y J, et al. Classifying ischemic stroke, from TOAST to CISS［J］. CNS Neurosci Ther, 2012, 18(6): 452-456.
［2］ Wang Y J, Wang Y L, Zhao X Q, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack［J］. N Engl J Med, 2013, 369(1): 11-19.
［3］ Wang Y L, Zhao X Q, Lin J X, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack［J］. JAMA, 2016, 316(1): 70-78.
［4］ Pan Y S, Chen W Q, Xu Y, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and Meta-analysis［J］. Circulation, 2017, 135(1): 21-33.
［5］ Wang Y, Chen W, Lin Y, et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial［J］. BMJ, 2019, 365, l2211.
［6］ Wang Y J, Meng X, Wang A X, et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA［J］. N Engl J Med, 2021, 385(27): 2520-2530.
［7］ Meng X, Wang A X, Zhang G J, et al. Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial［J］. Stroke Vasc Neurol, 2021, 6(2): 274-279.
［8］ Wang Y J, Jing J, Meng X, et al. The third China National Stroke Registry (CNSR-III) for patients with acute ischaemic stroke or transient ischaemic attack: design, rationale and baseline patient characteristics［J］. Stroke Vasc Neurol, 2019, 4(3): 158-164.
［9］ Wang Y J, Li S Y, Pan Y S, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial［J］. Lancet, 2023, 401(10377): 645-654.
［10］ Xiong Y, Campbell B C V, Schwamm L H, et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy［J/OL］. N Engl J Med.［2024-06-14］. https://pubmed.ncbi.nlm.nih.gov/38884324/.
［11］ Li S, Gu H Q, Li H, et al. Reteplase versus alteplase for acute ischemic stroke［J/OL］. N Engl J Med. ［2024-06-14］. https://pubmed.ncbi.nlm.nih.gov/38884332/.
［12］ 国家卫生和计划生育委员会神经内科医疗质量控制中心. 中国卒中中心建设指南［J］. 中国卒中杂志, 2015(6): 499-507.
［13］ 王拥军. 卒中中心手册［M］. 北京: 人民卫生出版社, 2016.
［14］ Wang Y L, Li Z X, Zhao X Q, et al. Effect of a multifaceted quality improvement intervention on hospital personnel adherence to performance measures in patients with acute ischemic stroke in China: a randomized clinical trial［J］. JAMA, 2018, 320(3): 245-254.
［15］ 中国卒中学会组织. 中国脑血管病临床管理指南［M］. 2版. 北京: 人民卫生出版社, 2023.
［16］ 国家卫生健康委员会. 2022年国家医疗服务与质量安全报告［M］. 北京: 科学技术文献出版社, 2023.
［17］ 王拥军. 神经病学［M］. 4版. 北京: 北京大学医学出版社, 2019.
|
